Phase II study of dolastatin-10 in patients with advanced non-small-cell lung cancer Journal Article

  

Authors:	Krug, L. M.; Miller, V. A.; Kalemkerian, G. P.; Kraut, M. J.; Ng, K. K.; Heelan, R. T.; Pizzo, B. A.; Perez, W.; McClean, N.; Kris, M. G.
Article Title:	Phase II study of dolastatin-10 in patients with advanced non-small-cell lung cancer
Keywords:	adult; cancer chemotherapy; clinical article; treatment outcome; aged; middle aged; survival rate; clinical trial; advanced cancer; drug efficacy; antineoplastic agents; cancer staging; follow-up studies; quality of life; phase 2 clinical trial; lung non small cell cancer; neuropathy; carcinoma, non-small-cell lung; lung neoplasms; dose-response relationship, drug; febrile neutropenia; severity of illness index; oligopeptides; infusions, intravenous; non-small-cell lung cancer; dolastatin-10; dolastatin 10; humans; prognosis; human; male; female; priority journal; article
Journal Title:	Annals of Oncology
Volume:	11
Issue:	2
ISSN:	0923-7534
Publisher:	Oxford University Press
Date Published:	2000-02-01
Start Page:	227
End Page:	228
Language:	English
DOI:	10.1023/a:1008349209956
PUBMED:	10761761
PROVIDER:	scopus
DOI/URL:	http://www.scopus.com/inward/record.url?eid=2-s2.0-0034093431&partnerID=40&md5=a3a69c1247fdafed13554c0e9ff93470
Notes:	Export Date: 18 November 2015 -- Source: Scopus

https://synapse.mskcc.org/synapse/works/has_related_data_chk/84007